Xianglian Solution Veterinary Grade API is supplied as a concentrated liquid extract standardized to berberine-type alkaloid content, derived from the co-extraction of Coptis chinensis rhizome and Aucklandia lappa root. The material functions as an intermediate that is further processed into finished veterinary dosage forms for enteric bacterial indications in swine, poultry, and ruminants. The following application scenarios detail processing windows, formulation boundaries, and compliance requirements for each downstream format.

Tablet Compression and Aqueous Granulation Transfer Constraints

In tablet manufacture from concentrated herbal extract liquids, aqueous granulation transfer imposes specific constraints on binder selection, wet-mass rheology, and final granule moisture before compression. When Xianglian Solution is introduced as the granulating liquid at 8–15% w/w on dry solids basis, the dissolved alkaloid fraction and residual polysaccharide components from Coptis chinensis act as endogenous binders, reducing the requirement for synthetic polymer addition. Formulation trials using a high-shear granulator with a 25 L bowl and chopper speed of 1500 RPM demonstrate that acceptable granule growth is achieved with microcrystalline cellulose PH101 at 20–30% w/w and pregelatinized starch at 4–6% w/w. No additional PVP K30 is required when the API solids contribution exceeds 10% w/w; below that threshold, PVP K30 at 2–3% w/w dissolved in the granulating liquid prevents granule friability. Wet-mass screening through a 1.6 mm aperture produces granules that, after fluid-bed drying at 55–60°C inlet air temperature to a product temperature of 35–40°C, exhibit final moisture of 3.0–4.5% determined by loss on drying at 105°C for 5 h. Terminal granule size distribution should be controlled to 12–60 mesh, with fines below 60 mesh limited to ≤ 15% to avoid capping during compression. Final tablet formulations incorporate croscarmellose sodium at 2–5% w/w as disintegrant, colloidal silicon dioxide at 0.5–1.0% w/w as glidant, and magnesium stearate at 0.5–1.0% w/w as lubricant. Compression on a rotary tablet press at 8–18 kN main compaction force yields tablet hardness of 50–90 N and friability below 1.0% when tested per the Chinese Veterinary Pharmacopoeia (CVP) 2020 Edition. Disintegration in water at 37°C should complete within 30 min using the basket-rack apparatus described in CVP 2020 Appendix X A. Assay for berberine hydrochloride is performed by reversed-phase HPLC with a C18 column, mobile phase of acetonitrile and 0.1% phosphoric acid, and UV detection at 345 nm, following CVP 2020 Appendix 0512. Tablet core compression for multi-dose veterinary packs of 50, 100, and 1000 tablets should specify coated versus uncoated cores depending on taste-masking requirements in feed-administered formats.

Process transfer failures in tablet production are most frequently linked to granule moisture excursions exceeding 5.0% before compression, which trigger sticking on the lower punch faces and weight variation drift beyond ±5.0% RSD. On production-scale rotary presses running at 20–35 RPM with 37-station tooling, an increase in granule moisture from 4.0% to 5.5% is known to increase ejection force by approximately 40% and produce observable picking on embossed tooling within 15–20 min of continuous operation. Published data for Xianglian Solution specifically at this configuration is limited; the moisture sensitivity described reflects the general behavior of Coptis-derived extract granulations documented in pharmaceutical processing literature. Anti-adherent measures that address this failure mode include increasing magnesium stearate to 1.0% w/w, reducing compaction force to the lower bound of the 8–12 kN range, or extending pre-compression dwell time. Each intervention alters disintegration performance, requiring revalidation of the 30 min limit. Tablet cores incorporating herbal extract granulations should be stored in HDPE containers with heat-sealed aluminum foil induction liners to limit moisture uptake to below 0.5% weight gain per 12-month shelf-life interval at 25°C / 60% RH.

Because sterility assurance for injectable veterinary products demands bioburden reduction prior to final filtration, the API is typically received with a specified microbial count limit of ≤ 100 CFU/g and endotoxin burden below 0.5 EU/mg. Injectable formulations based on Xianglian Solution are prepared by diluting the concentrated extract in Water for Injection under aseptic conditions, with pH adjustment to 5.0–6.5 using 0.1 N hydrochloric acid or sodium hydroxide. The buffering capacity of the extract matrix is significant; trials demonstrate that approximately 0.3–0.5 mmol of titrant per 100 mL is required per 0.1 pH unit shift within the target window. This characteristic necessitates slow, controlled titration with continuous stirring at 200–300 RPM in a jacketed stainless-steel vessel maintained at 20–25°C. Tonicity adjustment to 280–320 mOsm/kg is accomplished with sodium chloride at 0.7–0.9% w/v or dextrose monohydrate at 4.5–5.5% w/v, verified by freezing-point depression osmometry per CVP 2020 Appendix 0632. The compounded solution passes through a sequence of depth filtration with 0.45 μm polyethersulfone (PES) prefilters followed by duplicate 0.22 μm sterilizing-grade PVDF membrane filters arranged in series. Filtration validation per ASTM F838-20 should demonstrate a log reduction value (LRV) of at least 7 for Brevundimonas diminuta at the process temperature. Bacterial endotoxin testing per CVP 2020 Appendix 1143 must produce values below 0.25 EU/mL in the finished injection. Filling is executed in an ISO 14644-1:2015 Class 5 cleanroom under Grade A laminar air flow, with automatic vial filling at 10–20 mL nominal volumes and stopper insertion followed by aluminum crimp sealing. Terminal sterilization at 121°C for 15 min is applicable only when the total extract solids fraction remains below 5.0% w/v; above that concentration, thermal degradation of alkaloid components produces color darkening and assay loss exceeding 5%. Formulations intended for intramuscular or subcutaneous administration in swine and cattle are therefore processed aseptically when extract solids exceed the 5.0% w/v threshold, per the stability rationale established in VICH GL9. Rubber stopper compatibility studies must evaluate extractive migration into the solution over 24-month storage at 25°C / 60% RH; chlorobutyl stoppers laminated with fluoropolymer film coatings demonstrate the lowest extractables profile. Headspace oxygen content should be controlled below 1.0% by nitrogen purging prior to capping to retard oxidative degradation of berberine-type alkaloids.

Injectable line validation for this API requires process simulation media fill runs achieving zero growth in ≥ 3000 consecutive units, executed at the maximum line speed and hold times anticipated in commercial production. Vial washing parameters, depyrogenation tunnel temperature profiles of 250°C for 30 min minimum dwell, and environmental monitoring data must be collated into the sterility assurance package. The rabbit pyrogen test (CVP 2020 Appendix 1142) is specified as a release test where the dose is 0.5 mL/kg administered intravenously, with a maximum temperature rise of 0.6°C across three animals. Batch records for injectable Xianglian Solution must document the traceability of each filter lot, integrity testing by bubble point or pressure hold, and post-filtration bioburden sampling per 10,000 vials produced. Aseptic processing produces a terminal product for the treatment of acute bacterial enteritis in pigs (Escherichia coli, Salmonella spp.) at doses of 0.1–0.2 mL/kg body weight per day, packaged in amber glass vials of 10 mL and 50 mL.

What Limits Gelatin Shell Moisture Sorption When Herbal Extract Powders Are Encapsulated?

Encapsulation throughput for herbal extract powders is frequently limited by the hygroscopicity of the dried matrix, not by the filling machine speed. When Xianglian Solution is converted to a dry intermediate via spray drying at 160–180°C inlet and 70–85°C outlet temperature, the resulting powder exhibits a moisture sorption isotherm that shows rapid uptake above 60% relative humidity. Powder transferred to hard gelatin capsule size 0 or 1 shells at ambient conditions of 55–65% RH will equilibrate to 5.0–7.0% moisture content within 4–6 h unless conditioned. The practical consequence is that fill weight variation drifts beyond ±5.0% as the powder volume density changes with moisture uptake, requiring an automatic capsule filler equipped with dosator or tamping-pin mechanisms to be recalibrated at intervals of 60–90 min during extended production campaigns. Addition of colloidal silicon dioxide at 1–2% w/w to the spray-dried intermediate reduces interparticle cohesion and improves flowability measured as Carr index below 25, or equivalently angle of repose below 40 degrees. For capsules with a target fill weight of 0.35–0.50 g, the formulation incorporates the spray-dried extract at 60–75% w/w, microcrystalline cellulose PH101 at 15–25% w/w, croscarmellose sodium at 3–5% w/w, and silicon dioxide at 1–2% w/w. Dissolution testing per CVP 2020 Appendix 0931 using Apparatus II (paddle) at 50 RPM in 900 mL of 0.1 N hydrochloric acid at 37°C should yield a Q value of at least 75% of label claim released within 45 min for the capsule dosage form. Delayed disintegration due to over-lubrication with magnesium stearate above 1.0% w/w is a recognized failure mode, since the hydrophobic lubricant film retards aqueous penetration into the hydrophilic extract matrix.

Moisture control in capsule production is enforced at three discrete points: incoming spray-dried powder must show loss on drying of ≤ 5.0% per CVP 2020 Appendix 0831; the encapsulating suite must be maintained at 20–25°C and 40–50% RH; and filled shells must be transferred to bulk packaging within 30 min of ejection from the filler. Hard gelatin shells in uncoated form lose mechanical integrity when shell moisture drops below 12% or exceeds 16%, producing split caps or telescoped bodies on the filling line. HPMC (hydroxypropyl methylcellulose) vegetarian shells show lower hygroscopicity under the same conditions but require lower fill speeds because of increased brittleness at 30–40% RH. Terminal products are packaged in PVC/aluminum or PVC/PVDC/aluminum blisters of 10 or 20 capsules, with desiccant sachets of 1–2 g silica gel included when the distribution chain crosses tropical climate zones. Long-term stability data per VICH GL9 support a shelf life of 24 months at 25°C / 60% RH where the berberine hydrochloride assay remains within 90–110% of label claim and dissolution Q does not fall below 75%. For feed-administered capsules in calves and foals, the veterinary dose range of 5–10 mg/kg body weight (expressed as berberine hydrochloride equivalent) determines the fill specification per unit.

For drinking water administration in intensive poultry and swine housing, soluble powder dosage forms require carriers that dissolve without residue in chlorinated water at 10–25°C. Xianglian Solution is converted to a soluble powder by adsorption onto a carrier system composed of lactose monohydrate at 60–80% w/w, anhydrous dextrose at 15–25% w/w, and maltodextrin DE10–15 at 5–15% w/w. The liquid API is sprayed onto the carrier blend in a ribbon mixer at a transfer efficiency of 95–100%, with the liquid dosing rate controlled at 3–5 L/min per 100 kg batch to avoid local overwetting and lump formation. Mixing continues for 20–30 min after liquid addition at 15–20 RPM shaft speed, followed by discharge through a 0.8 mm vibratory sieve. Blend uniformity is validated by sampling 10 points per batch using a thief probe and determining berberine hydrochloride content by HPLC; the coefficient of variation (CV) must not exceed 5.0%. Final moisture content of the soluble powder is controlled to ≤ 6.0% by loss on drying at 105°C for 5 h. Dissolution in tap water at 25°C should be complete within 10 min with gentle stirring, leaving no visible sediment or floating extract particles. The chlorination tolerance of the finished powder is relevant to field use: at free chlorine concentrations of 0.5–2.0 ppm typical of municipal and farm water sources, no measurable berberine degradation occurs over a 24 h contact window when the solution pH remains above 5.0. Packaging in laminated aluminum foil sachets of 100 g, 500 g, and 1 kg protects against moisture and light during storage. Reconstituted solution stability in the drinking water delivery system is 24–48 h depending on ambient temperature; at water temperatures above 30°C, fresh solution preparation is recommended within each 24 h cycle to prevent alkaloid sedimentation and biofilm accumulation in pipelines and nipple drinkers. Dosage rates in poultry follow 0.5–1.0 g/L drinking water for 3–5 consecutive days; in swine, 0.3–0.8 g/L is applied for 5–7 days to manage post-weaning colibacillosis.

Soluble powder production constraints emerge when the liquid API addition exceeds 25% w/w of the batch. Above this level, the carrier bed in a ribbon mixer transitions from free-flowing granular state to a cohesive mass, and discharge time through the sieve increases by a factor of three. The consequence is reduced batch throughput and elevated product temperature from mechanical friction, which accelerates the release of hygroscopic extract components. Where higher active loading is required, the API is first preconcentrated by vacuum evaporation at 60–70°C and −0.08 to −0.09 MPa to reduce the water load carried into the mixer, or the carrier blend is reformulated with additional lactose monohydrate to maintain the ≤ 25% w/w liquid addition limit. Equipment cleaning between batches on soluble powder lines follows alkaline detergent wash with 2% sodium hydroxide solution at 70°C, followed by citric acid rinsing at 1% and purified water flush until conductivity returns to ≤ 2.5 μS/cm. Cross-contamination testing by swab recovery of berberine fluorescence under UV light at 365 nm provides a rapid verification method with a target residue of ≤ 10 ppm.

When Feed Granule Drying Exceeds 58°C, Berberine Alkaloid Recovery Declines

Fluidised bed granulation of herbal extract blends for feed use proceeds through a defined moisture-evaporation window that controls agglomerate hardness. In granule production for oral administration to livestock, Xianglian Solution is employed as the liquid binder at 10–20% w/w of the dry powder charge, which consists of sucrose at 40–60% w/w, corn starch at 20–35% w/w, and microcrystalline cellulose at 5–15% w/w. The liquid extract is introduced through a top-spray nozzle at atomizing air pressure of 0.15–0.25 MPa and liquid flow rate of 50–80 mL/min per 10 kg batch, with inlet air temperature set at 65–75°C. Product bed temperature is maintained below 55°C throughout the spray phase. After the target solution volume is delivered, drying proceeds at 55–58°C inlet air until the exhaust air temperature indicates equilibrium moisture of 2.0–3.0% in the granulated product. The upper drying limit of 58°C is fixed by degradation kinetics of berberine hydrochloride; published thermal stability data for Coptis alkaloids indicate a decomposition onset near 160°C in pure crystalline form, but extract matrices show measurable assay loss above 60°C when drying is prolonged, attributed to co-occurring polysaccharide caramelization and Maillard-type interactions that sequester alkaloid species. Product temperature excursions above 60°C for sustained periods exceeding 30 min are associated with darkening and a 5–8% reduction in HPLC-determined berberine content relative to the theoretical load. Granulated material is screened to 12–60 mesh after drying, with oversize above 12 mesh milled through a low-speed oscillating granulator and fines below 60 mesh returned to the next batch as regranulation seed. Finished granules are filled into sachets of 50 g, 100 g, or 500 g for direct oral administration to piglets, or into bulk liners of 25 kg for subsequent dilution into farm mixing tanks.

Granule hardness, as measured by a tablet hardness tester on granule bed samples, should fall in the range of 10–25 N when tested on individual granules of 2–3 mm diameter. Granules that are too soft (≤ 5 N) disintegrate during packaging and transport, producing visible dust accumulation at the bottom of sachets, while granules that are too hard (≥ 40 N) resist dissolution in drinking water and may pass through the digestive tract of young animals without releasing active alkaloid. The dissolution behavior of the final granules in water at 37°C should achieve 80% release within 15 min when tested by the rotating-basket method adapted from CVP 2020 Appendix 0931. Because the product is administered in feed or as a top dress, palatability is relevant: sucrose in the formulation provides energy density and masks the inherent bitterness of Coptis-derived alkaloids. In finishing swine diets, the granules are mixed into feed at a rate equivalent to 50–100 ppm berberine hydrochloride in final ration, corresponding to 0.5–1.0 kg granules per tonne of feed. Granule production lines for veterinary botanical APIs are subject to cleaning validation using the same alkaline-acid sequence described for soluble powders, with swab limits set at ≤ 10 ppm berberine-equivalent residue.

Feed Premix Uniformity at 500 g/tonne Inclusion - A Ribbon Blender Validation Sequence

At inclusion rates below 1000 g per tonne of finished feed, premix homogeneity for botanical extract APIs is governed by the coefficient of variation determined from ten sampling points per batch. Xianglian Solution is converted to a feed premix by spraying the liquid extract onto a carrier of corn cob meal at 40–60% w/w, rice hull powder at 20–30% w/w, and calcium carbonate at 5–10% w/w in a horizontal ribbon blender of 500 kg working capacity. The spray system delivers the liquid API at 2–4 L/min through fan nozzles positioned in the upper third of the mixing trough, with the blender operating at 20–30 RPM. After liquid addition is complete, the mixing continues for 15–20 min; shorter mixing times produce CV values above 10%, while total mixing duration beyond 40 min generates fines through mechanical attrition of the carrier particles and reduces flowability. Sampling for uniformity is performed on the discharged premix using a slotted thief probe inserted at ten positions distributed across the batch, following the procedures in ISO 6497. The acceptance criterion is a coefficient of variation of ≤ 5.0% for berberine hydrochloride content determined by HPLC on each sample. Batches exceeding this limit are reprocessed through an additional 5 min mixing cycle, up to a maximum of three reprocessing events before entire batch rejection.

The premix is subsequently diluted into final feed at a rate of 500–1000 g/tonne, targeting a finished-feed berberine hydrochloride concentration of 30–60 ppm for prophylactic enteric control. The transition from concentrated premix to final feed requires a two-stage dilution sequence to avoid carryover and maintain uniformity: the first stage blends the premix into a 25 kg intermediate carrier charge, and the second stage distributes that intermediate into the 1000 kg main mixer. Validation of the two-stage sequence is conducted by sampling final feed at 10 points per 1000 kg load and confirming a CV of ≤ 10% for the active alkaloid. Carrier selection matters because the liquid extract displaces air in the porous corn cob matrix; carriers with oil absorption capacity below 50 g/100 g cannot retain the liquid load without developing a wet surface that causes caking during storage. Mineral oil is not required as a liquid binder because the extract itself performs that function. Anti-caking performance of calcium carbonate at 5–10% w/w is sufficient to prevent consolidation in 25 kg multi-wall paper bags with inner polyethylene liner during 6-month warehouse storage at 25°C / 60% RH. The finished premix carries a label claim stated as berberine hydrochloride content in grams per kilogram, with a shelf life of 12 months where assay retention remains within 90–110% of label claim per VICH GL9 long-term storage conditions.

Oral liquid formulations represent the most direct dilution pathway for Xianglian Solution, where the API is transferred to final container with minimal thermal history. The liquid extract is diluted with purified water in a mixing ratio determined by the target berberine hydrochloride concentration in the finished product, typically 0.3–1.0% w/v. Dilution is executed in a 316L stainless-steel mixing vessel under continuous propeller agitation at 100–150 RPM, with the API charged first and purified water added gradually to avoid localized pH stratification. The preservative system is selected based on the final use pattern and distribution climate: sodium benzoate at 0.1–0.2% w/v is effective only when the solution pH is maintained below 5.5, while potassium sorbate at 0.1–0.15% w/v active fraction covers a slightly broader pH range up to 6.0. Combined systems of sodium benzoate and potassium sorbate each at 0.05–0.1% are employed for tropical-region product registrations to pass antimicrobial effectiveness testing per CVP 2020 Appendix 1121. pH adjustment to 5.0–6.0 uses citric acid monohydrate at 0.05–0.2% w/v dissolved in a portion of the purified water prior to final volume adjustment. The finished solution is passed through a 100 μm polyester filter bag to remove incidental particulate matter, though full sterilizing filtration is not required for oral liquids when the microbial limit test (CVP 2020 Appendix 1106) shows total aerobic microbial count below 100 CFU/mL and absence of Escherichia coli in 1 mL. Amber polyethylene terephthalate (PET) bottles with polypropylene caps and induction-sealed aluminum foil liners protect the alkaloid component from photodegradation, which has been observed at light exposures above 1.2 million lux-hours in accelerated studies. Packaging configurations in common trade channels include 100 mL, 250 mL, 500 mL, and 1 L bottles, with dispensing pumps calibrated to deliver 5 mL per stroke for small-animal dosing. The viscosity of the finished oral liquid remains below 50 mPa·s at 25°C, suitable for automated filling lines at speeds up to 120 bottles/min without foaming or drip. Long-term stability per VICH GL9 at 25°C / 60% RH supports 24-month shelf life with berberine hydrochloride assay maintained at 90–110% of label claim; intermediate stress conditions of 30°C / 65% RH over 12 months provide supporting data for Zone III and IV distribution markets.

Oral solution production includes an incompatibility constraint that must be documented in manufacturing instructions: the extract must not be combined with amine-based alkalizing agents or strong oxidizing preservatives such as sodium hypochlorite, because both trigger precipitation of berberine-type alkaloids from the aqueous medium. Where combination products with other antimicrobial agents are required, compatibility studies in the final container should be conducted over 14 days at 25°C and 40°C to evaluate precipitate formation, color shift, and assay retention for each active component. The oral liquid format serves as the reference dosage form for pharmacokinetic studies in target species, where the absorption of berberine hydrochloride after oral administration in swine is characterized by a bioavailability below 5% due to P-glycoprotein-mediated efflux in the intestinal epithelium, supporting the clinical rationale for repeated dosing over 3–7 days rather than single-dose therapy.